Ipamorelin has a human record and a vendor convention, and the two are not even in the same order of magnitude. Every dose a person has received in a published study was intravenous, and the two trials that matter used 0.03 to 0.06 mg/kg, a few milligrams at a time. The figures on vendor pages are hundreds of micrograms, subcutaneously, several times a day. This page reports both, keeps them apart, and works the units for the 5 mg and 10 mg vials the site's calculator uses.
Ipamorelin is a five-amino-acid growth-hormone secretagogue that acts at the ghrelin receptor, designed in the 1990s to release growth hormone without the cortisol and prolactin rise of the earlier GHRPs. Medibact's Ipamorelin guide covers the molecule, the receptor and the evidence; this page stays with figures. The dosage hub lists every compound's page; the CJC-1295 + Ipamorelin page covers the blend and the CJC-1295 page its usual partner.
What the sources state
| Source | Kind | Route | Figure | Date read |
|---|---|---|---|---|
| DailyMed search, "ipamorelin" | Label search | Any | Zero records; no approved product | 2026-09-18 |
| Gobburu et al., Pharmaceutical Research 1999 (PMID 10496658) | Trial publication (pharmacokinetics) | Intravenous, 15-minute infusion | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg (about 3, 10, 30, 60 and 100 mcg/kg, this page's conversion); healthy volunteers; terminal half-life 2 hours; SC50 for GH 214 nmol/L | 2026-09-18 |
| Beck et al., International Journal of Colorectal Disease 2014 | Trial publication (phase 2) | Intravenous | 0.03 mg/kg twice daily, postoperative days 1 to 7; 114 patients; 25.3 vs 32.6 hours to first tolerated meal, p=0.15 | 2026-09-18 |
| NCT01280344, Helsinn, phase 2, started April 2011, completed | Trial protocol | Intravenous | 0.03 mg/kg twice daily; 0.06 mg/kg twice daily; 0.06 mg/kg three times daily; saline control | 2026-09-18 |
| NCT00672074, phase 2, started April 2008, completed | Trial protocol | Intravenous | Ipamorelin versus placebo for postoperative ileus; no dose posted | 2026-09-18 |
| Raun et al., European Journal of Endocrinology 1998 (PMID 9849822) | Animal pharmacology | Intravenous | ED50 80 nmol/kg (rat), 2.3 nmol/kg (pig); no ACTH or cortisol release | 2026-09-18 |
| Johansen et al., Growth Hormone and IGF Research 1999 | Animal study | Subcutaneous (rats) | 18, 90 or 450 mcg per day in three doses for 15 days; dose-dependent bone growth | 2026-09-18 |
| Vendor and protocol pages (two opened) | Commonly cited | Subcutaneous | 100 to 300 mcg per injection, 1 to 3 times daily; 200 to 300 mcg a day; 8 to 12 weeks on, 4 off; 100 mcg 2 to 3 times daily; "past 300 mcg, GH release does not climb meaningfully" | 2026-09-18 |
The vendor figure and the trial figure differ by route and by roughly an order of magnitude, and the difference is not a disagreement about the right amount. The trials were asking whether an intravenous ghrelin mimetic would restart the bowel after surgery; the vendor pages describe a pulsed subcutaneous convention that no study has tested.
The per-kilogram figures in milligrams and micrograms
The 1999 infusion rates are given in nanomoles per kilogram, which is why they look unfamiliar. Multiplying by ipamorelin's molecular weight (711.9 g/mol, PubChem) turns 4.21 nmol/kg into 3.0 mcg/kg and 140.45 nmol/kg into 100 mcg/kg; the five levels were 3, 10, 30, 60 and 100 mcg/kg. At 70 kg they are 0.21, 0.70, 2.1, 4.2 and 7.0 mg, each given once over 15 minutes into a vein. The 2014 trial's 0.03 mg/kg is 2.1 mg at 70 kg, twice a day; the registered 0.06 mg/kg is 4.2 mg. Those conversions are this page's arithmetic, not the papers'.
Units per dose at each research-vial size
Research-market ipamorelin is supplied in 5 mg and 10 mg vials. The table takes each at 1, 2 and 3 mL, states the concentration, and converts the vendor figures (100, 200 and 300 mcg) and the two trial figures at 70 kg (2.1 mg and 4.2 mg) into U-100 syringe units, where 100 units is 1 mL (MedlinePlus, read 2026-09-18); the site's insulin syringe units page covers the syringe reading itself. The trial figures are shown only to make the scale visible; they were intravenous doses and are not draws anyone made from a research vial.
| Vial | Water added | Concentration | 100 mcg | 200 mcg | 300 mcg | 2.1 mg | 4.2 mg |
|---|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 2 | 4 | 6 | 42 | 84 |
| 5 mg | 2 mL | 2.5 mg/mL | 4 | 8 | 12 | 84 | 168 (>1 syringe) |
| 5 mg | 3 mL | 1.67 mg/mL | 6 | 12 | 18 | 126 (>1 syringe) | 252 (>1 syringe) |
| 10 mg | 1 mL | 10 mg/mL | 1 | 2 | 3 | 21 | 42 |
| 10 mg | 2 mL | 5 mg/mL | 2 | 4 | 6 | 42 | 84 |
| 10 mg | 3 mL | 3.33 mg/mL | 3 | 6 | 9 | 63 | 126 (>1 syringe) |
A 5 mg vial holds twenty-five 200 mcg amounts and a 10 mg vial fifty, whichever water volume is used; the vendor page's "about 50 days at 200 mcg a day" is that arithmetic. A single unit, which 100 mcg becomes at 10 mg/mL, is the smallest mark on the syringe, which is why the microgram convention adds water. The ipamorelin calculator works any combination entered, the site's ipamorelin reconstitution page covers water volumes per vial and the mixing steps as references describe them, and the reconstitution chart lists the same concentrations for every compound.
What the figures omit
The trial figures carry a population (surgical patients; healthy volunteers), an intravenous route, a schedule and a seven-day duration; they say nothing about subcutaneous use, about repeated weeks, or about growth-hormone endpoints outside a research ward. The vendor figures carry a route and a frequency and an 8-to-12-week course with a rest, none of it from a study; the timing rules (bedtime, fasted, hours after a meal) rest on the peptide's two-hour half-life and on growth-hormone physiology, not on a trial of the schedule. Neither set states a population, and neither says what happens across repeated cycles, because nobody has followed one.
What this page does not do
This page reports figures with their sources and dates and converts them into syringe units at the site's vial sizes. It does not recommend a dose, a route, a frequency or a course for anyone, does not say whether the vendor convention works, and does not turn it into advice. The mixing steps and the storage of a mixed vial are the store's topics: how to reconstitute peptides and how to store peptides on medibact.com.
Sources and dates
Opened 2026-09-18: the DailyMed SPL search API for "ipamorelin" (zero records); PubMed through the NCBI E-utilities for the census (50 records) and the abstracts of PMIDs 9879640, 9849822, 9733496, 9733495, 10496658, 10427162, 10373343, 25331030, 24574167 and 23318763; the ClinicalTrials.gov v2 API for "ipamorelin" (three records); PubChem for the molecular weight (CID 9831659); two vendor and protocol pages; and MedlinePlus for the U-100 definition. Corrections go to the contact page.